{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040949","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.806617+00:00","generated_at":"2026-06-11T17:02:34.085354+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eledon reports Q2 net loss $9.6M; cash $71.4M; raises up to $185M","bullets":["Net loss of $9.6M ($0.40 per share) in Q2 2023 vs $9.2M ($0.65 per share) in Q2 2022.","Cash and short-term investments totaled $71.4M at June 30, 2023, up from $56.4M at Dec 31, 2022.","Closed financing worth up to $185M, including $35M upfront, to fund through Phase 2 BESTOW trial.","Ninth patient dosed in Phase 1b kidney transplant trial; updated data expected Q4 2023.","Preclinical study shows subcutaneous tegoprubart formulation safe with similar blood levels."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040949","json":"https://secwatch.observer/filing/0000950170-23-040949.json","markdown":"https://secwatch.observer/filing/0000950170-23-040949.md","text":"https://secwatch.observer/filing/0000950170-23-040949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023040949/0000950170-23-040949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023040949/eldn-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:02:34.085354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2fbf956405f6afd5b9f43123b16f3e81c9f2085c","claim":"Eledon Pharmaceuticals, Inc. reported second quarter results: net income net loss of $9.6 million, or $0.40 per share, EPS $0.40 per share.","evidence_excerpt":"The company reported a net loss of $9.6 million, or $0.40 per share, for the three months ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023040949/0000950170-23-040949-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter"},{"label":"Net income","value":"net loss of $9.6 million, or $0.40 per share"},{"label":"EPS","value":"$0.40 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}